218 related articles for article (PubMed ID: 34448414)
1. Ototoxicity and Teprotumumab.
Highland J; Gordon S; Reddy D; Patel N
Ann Otol Rhinol Laryngol; 2022 Aug; 131(8):910-913. PubMed ID: 34448414
[TBL] [Abstract][Full Text] [Related]
2. Teprotumumab-associated chronic hearing loss screening and proposed treatments.
Chow A; Silkiss RZ
BMJ Case Rep; 2022 Apr; 15(4):. PubMed ID: 35418378
[TBL] [Abstract][Full Text] [Related]
3. Sensorineural Hearing Loss After Teprotumumab Therapy for Thyroid Eye Disease: A Case Report.
Ding AS; Mahoney NR; Campbell AA; Creighton FX
Otol Neurotol; 2022 Feb; 43(2):e148-e152. PubMed ID: 34789694
[TBL] [Abstract][Full Text] [Related]
4. Reduction of Teprotumumab-Induced Hearing Loss With Comparable Efficacy Using Half-Dose Therapy.
Phansalkar R; Lu T; Alyono J; Lee J; Dosiou C; Kossler AL
Ophthalmic Plast Reconstr Surg; 2023 Jul-Aug 01; 39(4):e101-e104. PubMed ID: 36877549
[TBL] [Abstract][Full Text] [Related]
5. Hearing Dysfunction After Treatment With Teprotumumab for Thyroid Eye Disease.
Sears CM; Azad AD; Amarikwa L; Pham BH; Men CJ; Kaplan DN; Liu J; Hoffman AR; Swanson A; Alyono J; Lee JY; Dosiou C; Kossler AL
Am J Ophthalmol; 2022 Aug; 240():1-13. PubMed ID: 35227694
[TBL] [Abstract][Full Text] [Related]
6. Thyroid Eye Disease, Teprotumumab, and Hearing Loss: An Evolving Role for Otolaryngologists.
Chern A; Dagi Glass LR; Gudis DA
Otolaryngol Head Neck Surg; 2021 Dec; 165(6):757-758. PubMed ID: 33781112
[TBL] [Abstract][Full Text] [Related]
7. Teprotumumab for Graves' orbitopathy and ototoxicity: moving problems from eyes to ears?
Bartalena L; Marinò M; Marcocci C; Tanda ML
J Endocrinol Invest; 2022 Jul; 45(7):1455-1457. PubMed ID: 35403994
[No Abstract] [Full Text] [Related]
8. Teprotumumab for patients with active thyroid eye disease: a pooled data analysis, subgroup analyses, and off-treatment follow-up results from two randomised, double-masked, placebo-controlled, multicentre trials.
Kahaly GJ; Douglas RS; Holt RJ; Sile S; Smith TJ
Lancet Diabetes Endocrinol; 2021 Jun; 9(6):360-372. PubMed ID: 33865501
[TBL] [Abstract][Full Text] [Related]
9. Teprotumumab for the treatment of thyroid eye disease.
Ju Y; Yang J
Expert Rev Clin Immunol; 2020 Aug; 16(8):739-743. PubMed ID: 32707005
[TBL] [Abstract][Full Text] [Related]
10. Reply to Letter to the Editor by Dr. Terry J. Smith regarding teprotumumab and ototoxicity.
Bartalena L; Marcocci C; Tanda ML; Marinò M
J Endocrinol Invest; 2022 Aug; 45(8):1603-1604. PubMed ID: 35633498
[No Abstract] [Full Text] [Related]
11. Rifle Blast Exacerbating Hearing Loss in a Patient Treated With Teprotumumab for Thyroid Eye Disease.
Reed DS; Kostosky N; Davies BW; Epstein A; Durairaj VD
Ophthalmic Plast Reconstr Surg; 2022 Mar-Apr 01; 38(2):e41-e43. PubMed ID: 34652314
[TBL] [Abstract][Full Text] [Related]
12. Teprotumumab: A Review in Thyroid Eye Disease.
Nie T; Lamb YN
Drugs; 2022 Nov; 82(17):1663-1670. PubMed ID: 36418673
[TBL] [Abstract][Full Text] [Related]
13. Oral Corticosteroids for Teprotumumab-Related Hearing Loss: A Case Report.
Lu TJ; Amarikwa L; Winn BJ; Inserra M; Dosiou C; Kossler AL
Case Rep Ophthalmol; 2023; 14(1):134-139. PubMed ID: 37034380
[TBL] [Abstract][Full Text] [Related]
14. Teprotumumab: First Approval.
Markham A
Drugs; 2020 Apr; 80(5):509-512. PubMed ID: 32157641
[TBL] [Abstract][Full Text] [Related]
15. Teprotumumab and Hearing Loss: Case Series and Proposal for Audiologic Monitoring.
Belinsky I; Creighton FX; Mahoney N; Petris CK; Callahan AB; Campbell AA; Kazim M; Lee HBH; Yoon MK; Dagi Glass LR
Ophthalmic Plast Reconstr Surg; 2022 Jan-Feb 01; 38(1):73-78. PubMed ID: 34085994
[TBL] [Abstract][Full Text] [Related]
16. Teprotumumab: a novel therapeutic monoclonal antibody for thyroid-associated ophthalmopathy.
Slentz DH; Nelson CC; Smith TJ
Expert Opin Investig Drugs; 2020 Jul; 29(7):645-649. PubMed ID: 32429706
[TBL] [Abstract][Full Text] [Related]
17. Teprotumumab for the Treatment of Active Thyroid Eye Disease.
Douglas RS; Kahaly GJ; Patel A; Sile S; Thompson EHZ; Perdok R; Fleming JC; Fowler BT; Marcocci C; Marinò M; Antonelli A; Dailey R; Harris GJ; Eckstein A; Schiffman J; Tang R; Nelson C; Salvi M; Wester S; Sherman JW; Vescio T; Holt RJ; Smith TJ
N Engl J Med; 2020 Jan; 382(4):341-352. PubMed ID: 31971679
[TBL] [Abstract][Full Text] [Related]
18. Teprotumumab: Interpreting the Clinical Trials in the Context of Thyroid Eye Disease Pathogenesis and Current Therapies.
Winn BJ; Kersten RC
Ophthalmology; 2021 Nov; 128(11):1627-1651. PubMed ID: 33930408
[TBL] [Abstract][Full Text] [Related]
19. Prospective Assessment of Otologic Adverse Events due to Teprotumumab: Preliminary Results.
Kay-Rivest E; Belinsky I; Kozlova A; Byrd E; McMenomey SO; Jethanamest D
Otolaryngol Head Neck Surg; 2023 May; 168(5):1164-1169. PubMed ID: 36939482
[TBL] [Abstract][Full Text] [Related]
20. The Adverse Effects Profile of Teprotumumab.
Stan MN; Krieger CC
J Clin Endocrinol Metab; 2023 Aug; 108(9):e654-e662. PubMed ID: 37071658
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
